PT - JOURNAL ARTICLE AU - Howlett-Prieto, Quentin AU - Oommen, Chelsea AU - Carrithers, Michael D. AU - Wunsch, Donald C. AU - Hier, Daniel B. TI - Subtypes of Relapsing-Remitting Multiple Sclerosis Identified by Network Analysis AID - 10.1101/2022.11.16.22282420 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.16.22282420 4099 - http://medrxiv.org/content/early/2022/11/18/2022.11.16.22282420.short 4100 - http://medrxiv.org/content/early/2022/11/18/2022.11.16.22282420.full AB - The objective of this study was to use network analysis to identify subtypes of relapsing-remitting multiple sclerosis subjects based on their cumulative signs and symptoms. We reviewed the electronic medical records of 120 subjects with relapsing-remitting multiple sclerosis and recorded signs and symptoms. Signs and symptoms were mapped to a neuroontology and then collapsed into 16 superclasses by subsumption and normalized. Bipartite (subject-feature) and unipartite (subject-subject) network graphs were created using Gephi. Degree and weighted degree were calculated for each node. Graphs were partitioned into communities using the modularity score. Feature maps were used to visualize differences in features by the community. Network analysis of the unipartite graph yielded a higher modularity score (0.49) than the bipartite graph (0.247). Network analysis can partition multiple sclerosis subjects into communities based on signs and symptoms. Communities of subjects with predominant motor, sensory, pain, fatigue, cognitive, behavior, and fatigue features were found. Larger datasets and additional partitioning algorithms are needed to confirm these results and elucidate their clinical significance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMDC acknowledges research funding from the Department of Veterans Affairs (BLR\&D Merit Award BX000467) and prior support from Biogen. DCW II acknowledges research funding support from the Mary K. Finley Endowment at the Missouri University of Science and Technology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the University of Illinois at ChicagoI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors